Sinovac Biotech Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
2,602
- Stock Symbol
-
SVA
- Investments
-
6
- Share Price
-
$6.47
- (As of Friday Closing)
Sinovac Biotech General Information
Description
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
Contact Information
Website
www.sinovacbio.comCorporate Office
- Number 39, Shangdi West Road
- Haidian District
- Beijing, 100085
- China
Corporate Office
- Number 39, Shangdi West Road
- Haidian District
- Beijing, 100085
- China
Sinovac Biotech Stock Performance
As of 22-Feb-2019, Sinovac Biotech’s stock price is $6.47. Its current market cap is $460M with 71.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.47 | $6.49 | $5.73 - $8.75 | $460M | 71.1M | 15.4K | $0.34 |
Sinovac Biotech Financials Summary
As of 30-Jun-2026, Sinovac Biotech has a trailing 12-month revenue of $403M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| Revenue | 402,822 | 386,013 | 361,374 | 470,170 |
| EBITDA | (166,368) | (184,526) | 132,937 | (5,936) |
| Net Income | (98,251) | (59,680) | 90,905 | (13,491) |
| Total Assets | 8,138,788 | 8,541,725 | 12,337,281 | 13,657,974 |
| Total Debt | 390,285 | 505,616 | 391,323 | 298,983 |
Sinovac Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sinovac Biotech Comparisons
Industry
Financing
Details
Sinovac Biotech Competitors (32)
One of Sinovac Biotech’s 32 competitors is Sinopharm Group, a Corporation company based in Hong Kong, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sinopharm Group | Corporation | Hong Kong, China | ||||
| CanSino Biologics | Formerly VC-backed | Tianjin, China | ||||
| Protalix Biotherapeutics | Formerly VC-backed | Karmiel, Israel | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Sinovac Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sinovac Biotech Patents
Sinovac Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4272755-A1 | Combined vaccine for preventing hand, foot and mouth disease, preparation method therefor and use thereof | Pending | 30-Dec-2020 | ||
| EP-4272755-A4 | Combined vaccine for preventing hand, foot and mouth disease, preparation method therefor and use thereof | Pending | 30-Dec-2020 | ||
| WO-2022141266-A1 | Combined vaccine for preventing hand, foot and mouth disease, preparation method therefor and use thereof | Inactive | 30-Dec-2020 | ||
| WO-2021209060-A1 | Inactivated vaccine for sars-cov-2 and preparation thereof | Inactive | 17-Apr-2020 | ||
| WO-2021129246-A1 | Monoclonal antibody of coxsackie virus a10 type solid virus and use thereof | Inactive | 27-Dec-2019 | C07K16/106 |
Sinovac Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sinovac Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sinovac Biotech Investments & Acquisitions (6)
Sinovac Biotech’s most recent deal was a Later Stage VC with Synermore. The deal was made on 26-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Synermore | 26-Apr-2024 | Later Stage VC | Drug Discovery | ||
| Eva Heart | 09-Mar-2023 | PE Growth/Expansion | Other Devices and Supplies | ||
| CytoNiche | 03-Mar-2022 | Early Stage VC | Discovery Tools (Healthcare) | ||
| JYSS BIO | 04-Jan-2022 | Later Stage VC | Biotechnology | ||
| Sinovac LS | 31-Aug-2010 | Merger/Acquisition | Pharmaceuticals |
Sinovac Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Sinovac Biotech Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sinovac LS | Beijing, China | 2009 |
Sinovac Biotech FAQs
-
When was Sinovac Biotech founded?
Sinovac Biotech was founded in 1999.
-
Where is Sinovac Biotech headquartered?
Sinovac Biotech is headquartered in Beijing, China.
-
What is the size of Sinovac Biotech?
Sinovac Biotech has 2,602 total employees.
-
What industry is Sinovac Biotech in?
Sinovac Biotech’s primary industry is Pharmaceuticals.
-
Is Sinovac Biotech a private or public company?
Sinovac Biotech is a Public company.
-
What is Sinovac Biotech’s stock symbol?
The ticker symbol for Sinovac Biotech is SVA.
-
What is the current stock price of Sinovac Biotech?
As of 22-Feb-2019 the stock price of Sinovac Biotech is $6.47.
-
What is the current market cap of Sinovac Biotech?
The current market capitalization of Sinovac Biotech is $460M.
-
What is Sinovac Biotech’s current revenue?
The trailing twelve month revenue for Sinovac Biotech is $403M.
-
Who are Sinovac Biotech’s competitors?
Sinopharm Group, CanSino Biologics, Protalix Biotherapeutics, Novartis, and Merck & Co. are some of the 32 competitors of Sinovac Biotech.
-
What is Sinovac Biotech’s annual earnings per share (EPS)?
Sinovac Biotech’s EPS for 12 months was $0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
